Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study for Phase l is to determine the maximum tolerated dose of
panobinostat given in combination with carfilzomib, lenalidomide, and dexamethasone in 28-day
cycles as induction (initial) therapy to participants with newly diagnosed multiple myeloma.
In Phase ll, investigators will evaluate the safety (side effects) and efficacy
(effectiveness) of panobinostat in combination with carfilzomib, lenalidomide, and
dexamethasone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute